Market Cap 4.00B
Revenue (ttm) 0.00
Net Income (ttm) -413.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 829,500
Avg Vol 1,638,798
Day's Range N/A - N/A
Shares Out 175.28M
Stochastic %K 37%
Beta 0.56
Analysts Strong Sell
Price Target $38.80

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 580 3099
Address:
320 West 37th Street, 6th Floor, New York, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:20 AM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $22.91, showing a balanced RSI of 50.54, indicating neither overbought nor oversold conditions. The stock is positioned above its 30-day moving average (MA30) of $22.97, suggesting potential bullish momentum, while the 50-day moving average (MA50) of $20.63 provides a solid support level. Directional Bias: Given the proximity to the 60-day high of $26.17 and the recent trading range (high of $26.17 and low of $14.58), there's potential for upward movement. The ATR of 1.13 indicates moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $22.91 - Stop Loss: $21.50 (approx. 6.2% below entry) - Take Profit Targets: 1. $24.50 (7% ROI) 2. $25.50 (14% ROI) 3. $26.85 (17.5% ROI) This plan allows for a strategic entry with a favorable risk-reward ratio. Monitor closely for any changes in market sentiment. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:55 PM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $22.91, showing a balanced RSI of 50.54, indicating neither overbought nor oversold conditions. The stock is positioned above its 30-day moving average (MA30) of $22.97, suggesting potential bullish momentum, while the 50-day moving average (MA50) of $20.63 provides a solid support level. Directional Bias: Given the proximity to the 60-day high of $26.17 and the recent trading range (high of $26.17 and low of $14.58), there's potential for upward movement. The ATR of 1.13 indicates moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $22.91 - Stop Loss: $21.50 (approx. 6.2% below entry) - Take Profit Targets: 1. $24.50 (7% ROI) 2. $25.50 (14% ROI) 3. $26.85 (17.5% ROI) This plan allows for a strategic entry with a favorable risk-reward ratio. Monitor closely for any changes in market sentiment. https://privateprofiteers.com
0 · Reply
CH_Expat
CH_Expat Nov. 21 at 5:34 PM
$IMVT Did not have the balls. Maybe not too late.
0 · Reply
RonIsWrong
RonIsWrong Nov. 14 at 3:54 PM
$IMVT 👀👀
0 · Reply
SpaceCityKid
SpaceCityKid Nov. 12 at 2:19 PM
$IMVT In a beautiful falling flag. It's getting ready to rip
0 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Nov. 11 at 12:42 PM
$IMVT "Immunovant stock rating reiterated by Oppenheimer, cites progress in autoimmune portfolio" Price target $ 54. https://www.investing.com/news/analyst-ratings/immunovant-stock-rating-reiterated-by-oppenheimer-cites-progress-in-autoimmune-portfolio-93CH-4348781
0 · Reply
d_risk
d_risk Nov. 10 at 4:12 PM
$IMVT - Immunovant Inc. Common Stock - 10Q - Updated Risk Factors IMVT flags heightened risk from dependence on HanAll license for core IP; loss or breach could seriously impact operations. #Biotechnology #Pharmaceutical #OperationalRisk #LicenseDependency #IntellectualPropertyRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-Q/2025-11-10
0 · Reply
Pika_Capital
Pika_Capital Nov. 10 at 3:07 PM
$IMVT my best idea for 2026 probably. Buy this nonsense dip
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 2:03 PM
$IMVT (-10.1% pre) Immunovant, Inc. (IMVT) Misses Q2 EPS by 2c https://ooc.bz/l/83910
0 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Nov. 4 at 11:35 PM
$IMVT 📈🆙️🇺🇸💯
0 · Reply
Latest News on IMVT
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 12:31 PM EST - 27 days ago

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript


Why Immunovant Stock Blasted Higher Today

Sep 3, 2025, 6:17 PM EDT - 3 months ago

Why Immunovant Stock Blasted Higher Today


Top 2 Health Care Stocks That May Collapse This Quarter

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN


Immunovant Awarded U.S. Patent for IMVT-1402

Mar 12, 2024, 7:30 AM EDT - 1 year ago

Immunovant Awarded U.S. Patent for IMVT-1402


Best Small-Cap Stocks to Buy for 2024 and Beyond

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT


Immunovant to Present at Upcoming Investor Conferences

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences


Why Immunovant Stock Is Bolting Higher Today

Sep 27, 2023, 12:21 PM EDT - 2 years ago

Why Immunovant Stock Is Bolting Higher Today


Why Shares of Immunovant Are Soaring on Tuesday

Sep 26, 2023, 3:23 PM EDT - 2 years ago

Why Shares of Immunovant Are Soaring on Tuesday


These 2 Biotech Stocks Are Bucking a Down Market Tuesday

Sep 26, 2023, 9:10 AM EDT - 2 years ago

These 2 Biotech Stocks Are Bucking a Down Market Tuesday

ROIV


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:20 AM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $22.91, showing a balanced RSI of 50.54, indicating neither overbought nor oversold conditions. The stock is positioned above its 30-day moving average (MA30) of $22.97, suggesting potential bullish momentum, while the 50-day moving average (MA50) of $20.63 provides a solid support level. Directional Bias: Given the proximity to the 60-day high of $26.17 and the recent trading range (high of $26.17 and low of $14.58), there's potential for upward movement. The ATR of 1.13 indicates moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $22.91 - Stop Loss: $21.50 (approx. 6.2% below entry) - Take Profit Targets: 1. $24.50 (7% ROI) 2. $25.50 (14% ROI) 3. $26.85 (17.5% ROI) This plan allows for a strategic entry with a favorable risk-reward ratio. Monitor closely for any changes in market sentiment. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:55 PM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $22.91, showing a balanced RSI of 50.54, indicating neither overbought nor oversold conditions. The stock is positioned above its 30-day moving average (MA30) of $22.97, suggesting potential bullish momentum, while the 50-day moving average (MA50) of $20.63 provides a solid support level. Directional Bias: Given the proximity to the 60-day high of $26.17 and the recent trading range (high of $26.17 and low of $14.58), there's potential for upward movement. The ATR of 1.13 indicates moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $22.91 - Stop Loss: $21.50 (approx. 6.2% below entry) - Take Profit Targets: 1. $24.50 (7% ROI) 2. $25.50 (14% ROI) 3. $26.85 (17.5% ROI) This plan allows for a strategic entry with a favorable risk-reward ratio. Monitor closely for any changes in market sentiment. https://privateprofiteers.com
0 · Reply
CH_Expat
CH_Expat Nov. 21 at 5:34 PM
$IMVT Did not have the balls. Maybe not too late.
0 · Reply
RonIsWrong
RonIsWrong Nov. 14 at 3:54 PM
$IMVT 👀👀
0 · Reply
SpaceCityKid
SpaceCityKid Nov. 12 at 2:19 PM
$IMVT In a beautiful falling flag. It's getting ready to rip
0 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Nov. 11 at 12:42 PM
$IMVT "Immunovant stock rating reiterated by Oppenheimer, cites progress in autoimmune portfolio" Price target $ 54. https://www.investing.com/news/analyst-ratings/immunovant-stock-rating-reiterated-by-oppenheimer-cites-progress-in-autoimmune-portfolio-93CH-4348781
0 · Reply
d_risk
d_risk Nov. 10 at 4:12 PM
$IMVT - Immunovant Inc. Common Stock - 10Q - Updated Risk Factors IMVT flags heightened risk from dependence on HanAll license for core IP; loss or breach could seriously impact operations. #Biotechnology #Pharmaceutical #OperationalRisk #LicenseDependency #IntellectualPropertyRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-Q/2025-11-10
0 · Reply
Pika_Capital
Pika_Capital Nov. 10 at 3:07 PM
$IMVT my best idea for 2026 probably. Buy this nonsense dip
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 2:03 PM
$IMVT (-10.1% pre) Immunovant, Inc. (IMVT) Misses Q2 EPS by 2c https://ooc.bz/l/83910
0 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Nov. 4 at 11:35 PM
$IMVT 📈🆙️🇺🇸💯
0 · Reply
RonIsWrong
RonIsWrong Nov. 4 at 3:40 PM
$IMVT 👀👀
0 · Reply
Cyrus_C
Cyrus_C Nov. 3 at 10:43 AM
$IMVT very quiet, looks like its mostly tutes and very few retail here
0 · Reply
Quantum_Capital_LLC
Quantum_Capital_LLC Oct. 31 at 2:46 PM
$IMVT do your DD. Currently I am at +40% return and I am expecting a bigger return soon.
0 · Reply
RonIsWrong
RonIsWrong Oct. 30 at 2:25 PM
$IMVT Watching Immunovant; Shares Moving Higher, Traders Circulate Unconfirmed Rumor Co Mentioned By M&A Blog
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 30 at 2:20 PM
$IMVT "There's speculation that Immunovant has attracted takeover interest, according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday. One of the companies interested in buying Immunovant is Roivant (ROIV), Immunovant's largest shareholder."
0 · Reply
USA_toinfinity_andbeyond
USA_toinfinity_andbeyond Oct. 30 at 2:14 PM
$IMVT There's a lot more coming. The bullish scenario is around 55 bucks by January.
0 · Reply
Pika_Capital
Pika_Capital Oct. 30 at 2:08 PM
$IMVT if you listened to pika you would have been +60% ;)
0 · Reply
ChessGM
ChessGM Oct. 30 at 2:05 PM
$IMVT May I say: "potential buyout?". Very rare that stock is jumping 15% without any news. $IMVT volume is on track to exceed 90 day average volume...
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 30 at 2:02 PM
$IMVT Truist with egg on their face....silly PT of $16. The IB agendas will destroy retail if you let them.
0 · Reply
Pika_Capital
Pika_Capital Oct. 30 at 1:52 PM
$IMVT everyone hated it at $15. It's funny how sentiment can change in a month
0 · Reply